Stocks and Investing
Stocks and Investing
Tue, November 15, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Mon, November 14, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Yanan Zhu Maintained (ADAP) at Hold with Increased Target to $3 on, Nov 14th, 2022
Yanan Zhu of Wells Fargo, Maintained "Adaptimmune Therapeutics plc" (ADAP) at Hold with Increased Target from $1.5 to $3 on, Nov 14th, 2022.
Yanan has made no other calls on ADAP in the last 4 months.
There are 2 other peers that have a rating on ADAP. Out of the 2 peers that are also analyzing ADAP, 1 agrees with Yanan's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Nick Abbott of "Wells Fargo" Maintained at Hold with Decreased Target to $1.5 on, Tuesday, October 4th, 2022
This is the rating of the analyst that currently disagrees with Yanan
- Mara Goldstein of "Mizuho" Upgraded from Hold to Strong Buy and Held Target at $9 on, Wednesday, November 9th, 2022
Contributing Sources